The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The new centre brings advanced corneal procedures pioneered in India
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Subscribe To Our Newsletter & Stay Updated
